Antiparkinsonian Agents and Depot Phenothiazine
Abstract
To determine whether antiparkinsonian (AP) drugs should be regularly given prophylactically to all patients receiving depot antipsychotic drugs, the authors assigned 41 psychotic patients receiving fluphenazine enanthate to one of three groups. The first received only enough AP medication to control the occurrence of acute extrapyramidal symptoms (EPS), the second received AP medication for five days after each injection of depot fluphenazine, and the third received the AP agent daily. There were no significant differences among the three groups in the number and intensity of EPS, although some subjects in the first group displayed gross EPS that were controlled. The authors conclude that the routine prophylactic use of AP drugs is questionable but that further research is necessary.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
